• Klíčová slova
• PLEURODYNIA, EPIDEMIC/case reports *,
• MeSH
• chorobopisy * MeSH
• lidé MeSH
• myalgie * MeSH
• pleurodynie * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH

• Klíčová slova
• PLEURODYNIA *,
• MeSH
• bolesti na hrudi * MeSH
• pleurodynie * MeSH
• Publikační typ
• časopisecké články MeSH

INTRODUCTION: Protracted febrile myalgia syndrome (PFMS) is a rare manifestation of familial Mediterranean fever (FMF), characterized by myalgia, fever and elevated inflammatory markers lasting several weeks. As the hallmark of FMF are short episodes of disease symptoms, the long duration of PFMS may lead to a delayed diagnosis and treatment. OBJECTIVES: 1. To perform a review of literature and rheumatology textbooks focused on clinical features and treatment of PFMS in children. 2. To present our own case. METHODS: All articles in Pub Med generated using the keywords "protracted febrile myalgia" and information on PFMS in seven rheumatology textbooks were collected. The systematic review was supplemented with our own case presentation. RESULTS: In total, 18 articles with 78 pediatric patients (including our own) were retrieved. More than half of the patients presented with PFMS as the first manifestation of FMF. All complained of myalgia, 65% of abdominal pain and 26% had a rash. Corticosteroids (CS) were effective in 77%. In all CS-refractory cases, anakinra was shown efficient. MRI was used in 5 patients and showed myositis in all of them. The scrutiny of seven rheumatology textbooks showed that PFMS presenting with myalgia was mentioned in six. Possible accompanying symptoms were described only once, the long duration of symptoms twice, the efficacy of corticosteroids three times and anakinra only once. The presented 6 year old patient manifested with fever, myalgia, abdominal pain and petechial rash lasting 6 weeks. She had undergone multiple diagnostic procedures before her parents mentioned a positive family history for FMF. The subsequent genetic testing confirmed a homozygosity for M694V pathogenic variant in the MEFV gene. CONCLUSION: The long duration of PFMS may be misleading to clinicians especially if PFMS occurs at manifestation of FMF. The fact that more than half of the reported patients experienced PFMS as the presenting symptom of FMF is one of the key findings of our study. Our case presentation demonstrates the importance of genetic testing early in suspected autoinflammatory diseases. Furthermore, MRI may be an important diagnostic tool showing myositis in PFMS.

• Klíčová slova
• Clinical features, Diagnostic role of MRI, Protracted febrile myalgia syndrome, Treatment,
• MeSH
• dítě MeSH
• familiární středomořská horečka * komplikace   diagnóza   MeSH
• horečka * diagnóza   etiologie   MeSH
• lidé MeSH
• magnetická rezonanční tomografie metody   MeSH
• myalgie * diagnóza   etiologie   MeSH
• syndrom MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• systematický přehled MeSH

BACKGROUND: Gene SLCO1B1, encoding solute organic anionic transport polypeptide OATP1B1, belongs to the group of candidates potentially influencing statin treatment safety. OATP1B1 regulates (not only) the hepatic uptake of statins. Its genetic variation was described as an important predictor of statin-associated myopathy in a cohort of patients treated with a maximum dose of simvastatin. However, the impact of SLCO1B1 gene polymorphism on this risk in patients treated with other statins or lower doses of simvastatin needs to be assessed. Therefore, we performed the present study. MATERIAL/METHODS: SLCO1B1 tagging rs4363657 polymorphism was analyzed in 2 groups of patients with dyslipidemia (treated with simvastatin or atorvastatin, 10 or 20 mg per day), subgroup with statin-induced myalgia (N=286), and subgroup (N=707) without myalgia/myopathy, and in 2301 population controls without lipid-lowering treatment. RESULTS: Frequency of the individual genotypes in patients with myalgia/myopathy (TT=62.3%, CT=34.5%, CC=2.8%) did not significantly differ (both P values over 0.19) from that in patients without muscle symptoms (TT=61.4%, CT=32.9%, CC=5.7%) or from the population controls (TT=63.9%, CT=32.5%, CC=3.6%). Null results were also obtained for the dominant and recessive models of the analysis. CONCLUSIONS: In Czech patients treated with low statin doses, there is no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy.

• MeSH
• atorvastatin aplikace a dávkování   škodlivé účinky   farmakokinetika   terapeutické užití   MeSH
• diabetes mellitus epidemiologie   MeSH
• dyslipidemie farmakoterapie   genetika   MeSH
• frekvence genu MeSH
• genetická predispozice k nemoci MeSH
• genotyp MeSH
• hepatocyty metabolismus   MeSH
• jednonukleotidový polymorfismus * MeSH
• kouření epidemiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• modely genetické MeSH
• myalgie chemicky indukované   epidemiologie   genetika   MeSH
• nemoci svalů chemicky indukované   epidemiologie   genetika   MeSH
• obezita epidemiologie   MeSH
• polypeptid C přenášející organické anionty MeSH
• přenašeče organických aniontů genetika   fyziologie   MeSH
• senioři MeSH
• simvastatin aplikace a dávkování   škodlivé účinky   farmakokinetika   terapeutické užití   MeSH
• statiny aplikace a dávkování   škodlivé účinky   farmakokinetika   terapeutické užití   MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika epidemiologie   MeSH
• Názvy látek
• atorvastatin MeSH
• polypeptid C přenášející organické anionty MeSH
• přenašeče organických aniontů MeSH
• simvastatin MeSH
• SLCO1B1 protein, human MeSH Prohlížeč
• statiny MeSH

BACKGROUND: The gene COQ2, encoding 4-hydroxybenzoate-polyprenyltransferase (coenzyme Q2), belongs to the candidates potentially influencing statin treatment tolerability. This enzyme is involved in the biosynthesis of coenzyme Q10 (CoQ10), in which depletion induced by statin treatment is implicated in the development of statin-associated muscle symptoms (SAMS). Thus, polymorphisms in the COQ2 gene might explain susceptibility to SAMS. METHODS: Adult patients with SAMS (on low doses of atorvastatin and simvastatin)-induced myalgia/myopathy (n=278), patients on statins but without SAMS (n=293) and population (part of the post-MONICA [Multinational MONItoring of trends and determinants in CArdiovascular disease] study) controls (n=561) were genotyped (polymerase chain reaction-restriction fragment length polymorphism [PCR-RFLP] assay) for rs6535454 and rs4693075 polymorphisms within the COQ2 gene loci. RESULTS: Distribution of rs6535454 in patients with SAMS (GG=51.1%, GA=40.0%, AA=8.9%) did not significantly differ (p=0.33; respectively 0.32 for codominant models of the analysis) from that in the population controls (GG=48.1%, GA=45.0%, AA=6.9%) or the SAMS-unaffected patients (GG=49.8%, GA=40.3%, AA=9.7%). Similarly, neither rs4693075 was associated with SAMS (CC=36.8%, CG=48.2%, GG=15.0% in patients suffering SAMS vs. CC=36.6%, CG=47.5%, GG=15.9 in controls and CC=35.8%, CG=48.2%, GG=15.9% in symptom-free patients, p=0.94 and 0.95 for codominant models of the analysis). Also, the haplotype distributions were not significantly different between the groups analyzed. CONCLUSIONS: The polymorphisms of the COQ2 gene do not associate with SAMS in the Czech patients treated with low doses of statins. This is another clue that the coenzyme Q10 pathway is not the most important for the development of SAMS.

• Klíčová slova
• COQ2, coenzyme Q10, myalgia, myopathy, polymorphism, statin,
• MeSH
• běloši genetika   MeSH
• genetická predispozice k nemoci genetika   MeSH
• genotyp MeSH
• haplotypy MeSH
• lidé středního věku MeSH
• lidé MeSH
• nemoci svalů chemicky indukované   epidemiologie   genetika   MeSH
• polymorfismus genetický genetika   MeSH
• statiny škodlivé účinky   MeSH
• studie případů a kontrol MeSH
• ubichinon genetika   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky kontrolované MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika epidemiologie   MeSH
• Názvy látek
• statiny MeSH
• ubichinon MeSH
• Ubiquinone Q2 MeSH Prohlížeč

• MeSH
• atorvastatin škodlivé účinky   MeSH
• běloši genetika   MeSH
• lidé středního věku MeSH
• lidé MeSH
• myalgie chemicky indukované   genetika   MeSH
• pilotní projekty MeSH
• polymorfismus genetický genetika   MeSH
• ryanodinový receptor vápníkového kanálu genetika   MeSH
• senioři MeSH
• simvastatin škodlivé účinky   MeSH
• statiny škodlivé účinky   MeSH
• studie případů a kontrol MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• dopisy MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH
• Názvy látek
• atorvastatin MeSH
• ryanodinový receptor vápníkového kanálu MeSH
• simvastatin MeSH
• statiny MeSH

• Klíčová slova
• PLEURODYNIA, EPIDEMIC *,
• MeSH
• coxsackie virózy * MeSH
• epidemie * MeSH
• lidé MeSH
• pleurodynie * MeSH
• roční období * MeSH
• síla ruky * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH

The effectiveness and tolerability of the topical Symphytum product Traumaplant (Harras Pharma Curarina, München, Germany) (10% active ingredient of a 2.5:1 aqueous-ethanolic pressed concentrate of freshly harvested, cultivated comfrey herb [Symphytum uplandicum Nyman], corresponding to 25 g of fresh herb per 100 g of cream) in the treatment of patients with myalgia (n=104) were tested against a 1% reference product (corresponding to 2.5 g of fresh comfrey herb in 100 g of cream; n=111). The primary efficacy parameter in this double-blind, reference- controlled, randomized, multicenter study of 215 patients with pain in the lower and upper back was pain in motion, assessed with the aid of a visual analogue scale. Secondary efficacy parameters included pain at rest, pain on palpation, and functional impairment. With high concentrations of the treatment product, amelioration of pain on active motion (P<5 x 10 -9 ), pain at rest (P<.001), and pain on palpation (P=5 x 10 -5 ) was significantly more pronounced than that attained with the reference product and was clinically highly relevant. A number needed to treat of 3.2 was calculated from the study results. Global efficacy was significantly better (P=1 x 10 -8 ) and onset of effects was faster (P=4 x 10 -7 ) with the high-concentration product. Tolerability of the highly concentrated study product was good to excellent in all patients. Study results confirm the known anti-inflammatory and analgesic effects of topical (Symphytum cream. As a new finding, applicability in certain forms of back pain can be concluded.

• MeSH
• bolesti zad terapie   MeSH
• dospělí MeSH
• dvojitá slepá metoda MeSH
• fytoterapie MeSH
• kostival lékařský * MeSH
• lidé MeSH
• měření bolesti MeSH
• pohyb těles MeSH
• rostlinné přípravky terapeutické užití   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• rostlinné přípravky MeSH

• Klíčová slova
• NECK/diseases *, PERIARTHRITIS *, SHOULDER/diseases *,
• MeSH
• krční obratle * MeSH
• krk * MeSH
• lidé MeSH
• lopatka * MeSH
• myalgie * MeSH
• nemoc * MeSH
• periartritida * MeSH
• rameno * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH

• MeSH
• dítě MeSH
• infekce dýchací soustavy enzymologie   MeSH
• kreatinkinasa krev   MeSH
• lidé MeSH
• mladiství MeSH
• pleurodynie enzymologie   MeSH
• virové nemoci enzymologie   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• kreatinkinasa MeSH